Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of raltitrexed-containing TPF induction chemotherapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2100044072Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed, cisplatin and paclitaxel in head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Mar 2021; status: recruiting.
02
Drugs
raltitrexedcisplatinpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100044072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044072.